Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 21, 2024
RNS Number : 3895T Stifel Nicolaus Europe Limited 21 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 20, 2024
RNS Number : 2188T Stifel Nicolaus Europe Limited 20 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 19, 2024
RNS Number : 0651T Stifel Nicolaus Europe Limited 19 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 18, 2024
RNS Number : 8618S Stifel Nicolaus Europe Limited 18 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 17, 2024
RNS Number : 6843S Stifel Nicolaus Europe Limited 17 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

June 14, 2024
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc  (NASDAQ: RNLX) (LSE: RENX) announces that on June 13,

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 14, 2024
RNS Number : 4889S Stifel Nicolaus Europe Limited 14 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Medicare issues final Local Coverage Determination

June 14, 2024
RNS Number : 4910S Renalytix PLC 14 June 2024     This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR").

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 13, 2024
RNS Number : 3130S Stifel Nicolaus Europe Limited 13 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

PDMR Dealing

June 13, 2024
RNS Number : 2286S Renalytix PLC 13 June 2024     Renalytix plc ("Renalytix" or the "Company")   PDMR Dealing   LONDON  and  SALT LAKE CITY , 13 June 2024  -  Renalytix plc  (NASDAQ: RNLX) (LSE: RENX)   announces that the Board have granted Joel Jung , the interim Chief Financial Officer, options
Displaying 1 - 10 of 550